Luigi Costa
Board member
Medical Science
Oncopeptides
Sweden
Biography
Luigi Costa was appointed to the board of Oncopeptides in 2016 Luigi has over 20 years of experience in the international pharmaceutical and biotech industries. In addition to being a board member of Oncopeptide, Luigi is the CEO of Nordic Nanovector ASA, a public biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. Luigi’s previous positions include Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals where he led the company’s international organization and the prelaunch and launch of its multiple myeloma drug, Kyprolis® in markets outside the USA. Prior to joining Onyx Pharmaceuticals, Luigi held several leadership positions with Amgen, including Head of International Oncology Fanchise, General Manager of Amgen Italy and President of Amgen France, the company’s largest market outside the USA. He has also held various leadership positions with Eli Lilly both in Europe and America. Luigi holds a BSc in Business Administration from the University of Parma and an MBA from Bocconi Business School in Milan. Born: 1965 Board Committees: Member of the Audit Committee Holdings in Oncopeptides: 49 Share Options* Other current positions: CEO Nordic Nanovector ASA. Independent in relation to the Company, its senior management and major shareholders.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
